2024-10-29 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**1. Performance Comparison**

Pfizer Inc. (PFE) has underperformed the S&P 500 (VOO) significantly. While VOO has returned 136.36% cumulatively, PFE has experienced a -12.38% decline, resulting in a substantial divergence of -148.74%. This represents the lowest point in the historical range of relative divergence, indicating PFE's significant underperformance.

**2. Recent Price Action**

* **Closing Price:** $28.86 (Last Market: $28.87)
* **5-Day Moving Average:** $28.73
* **20-Day Moving Average:** $29.03
* **60-Day Moving Average:** $29.03

PFE's price is currently trading below its 5-day, 20-day, and 60-day moving averages, suggesting a short-term bearish trend. 

**3. Technical Indicators**

* **RSI:** 46.35: This value indicates a neutral sentiment, neither oversold nor overbought.
* **PPO:** -0.23: This indicates a bearish trend, as the PPO value is negative.
* **Delta_Previous_Relative_Divergence:** +0.62: This signifies a short-term upward trend in the stock's relative performance compared to the market. 
* **Expected Return:** 0.0%:  Currently, PFE is expected to yield a 0.0% long-term (2+ years) excess return compared to the S&P 500. This indicates that PFE may not provide significant outperformance compared to the benchmark index.

**4. Recent Earnings Performance and Outlook**

| Date       | EPS   | Expected EPS |
|------------|-------|---------------|
| 2024-07-30 | 0.60  | 0.458        |
| 2024-05-01 | 0.82  | 0.516        |
| 2024-01-30 | 0.10  | -0.19         |
| 2023-10-31 | -0.17 | -0.32         |
| 2023-08-01 | 0.67  | 0.56         |

Pfizer consistently exceeded earnings expectations in the last two quarters, with EPS reaching 0.60 and 0.82, respectively. However, the company's performance has been fluctuating, as seen in the Q4 2023 and Q1 2024 earnings, which fell short of estimates. 

The most recent earnings report (Q2 2024) indicates strong performance, with EPS of 0.60 exceeding the expectation of 0.458. This positive result suggests that Pfizer continues to manage its business effectively, despite ongoing challenges.

**5. Financial Trends Analysis**

| Item               | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|--------------------|---------------|---------------|---------------|
| Revenue            | $13.28B         | $14.88B         | $14.25B         | 
| Gross Profit       | $9.98B          | $11.50B         | $6.69B          | 
| Gross Margin %     | 75.16%          | 77.29%          | 46.92%          | 
| Operating Income   | $2.26B          | $4.20B          | $-1.97B         | 
| Operating Margin % | 17.04%          | 28.25%          | -13.83%         | 
| Net Income         | $0.04B          | $3.12B          | $-3.37B         | 
| Net Margin %       | 0.31%           | 20.94%          | -23.64%         | 
| EPS                | $0.01           | $0.55           | $-0.59          | 
| ROE %              | 0.05%           | 3.38%           | -3.78%          | 
| Total Assets       | $216.19B        | $221.09B        | $226.50B        | 
| Total Liabilities  | $128.22B        | $128.54B        | $137.21B        | 
| Total Equity       | $87.70B         | $92.28B         | $89.01B         | 
| Operating Cash Flow | $-1.78B         | $1.09B          | $5.24B          | 
| Capital Expenditure | $-0.64B         | $-0.70B         | $-1.04B         | 

Overall, the financial trends suggest a mixed picture. Revenue has been consistently strong, but the Gross Margin has declined in Q4 2023 due to various factors, including higher operating costs and supply chain disruptions. Profitability has been volatile, with significant swings in Operating Income, Net Income, and Net Margin. The recent positive earnings indicate potential improvement, but sustained profitability remains a key area to monitor. 

**6. News and Recent Issues**

**Recent Market Outlook:**

Pfizer's stock has faced significant challenges in recent months, primarily due to concerns about its COVID-19 vaccine sales declining, increased competition in the pharmaceutical industry, and rising operating costs. 

**Analyst Opinions:**

According to FINBOLD, analysts have a generally optimistic outlook on PFE's future performance, with an average price target of around $45 per share, suggesting a potential upside of about 55%. While recent performance may have dampened some enthusiasm, analysts remain confident in the company's long-term growth potential. 

**Performance Highlights:**

* **Strong earnings in Q2 2024:**  Pfizer exceeded earnings expectations, indicating positive momentum despite ongoing challenges.
* **Focus on pipeline innovation:** The company continues to invest heavily in research and development, particularly in areas like oncology, vaccines, and rare diseases.
* **Potential for growth in emerging markets:**  Pfizer is strategically focusing on expanding its presence in developing countries with high growth potential.

**7. Overall Analysis**

Pfizer (PFE) presents a complex investment case. While the company has demonstrated a history of strong performance, recent underperformance compared to the market and volatility in financial metrics raise concerns. However, positive earnings results and analysts' optimism for the long-term growth potential suggest that PFE may still offer upside potential.  Investors should carefully consider the company's financial trends, news developments, and analyst opinions before making any investment decisions. 
